Dajani A S
Wayne State University, Children's Hospital of Michigan, Detroit.
Drugs. 1988;35 Suppl 7:35-8. doi: 10.2165/00003495-198800357-00009.
The emergence and spread of ampicillin-resistant Haemophilus influenzae type b strains have led to a sharp reduction in the use of ampicillin, or the addition of chloramphenicol, in the initial therapy of serious childhood infections. In some instances, third generation cephalosporins are used instead. The combination of ampicillin with sulbactam restores the former usefulness of ampicillin and extends its spectrum of activity to include normally ampicillin-resistant Staphylococcus aureus. Sulbactam/ampicillin should be useful in treating bacterial meningitis. It is more effective than third generation cephalosporins against Listeria and enterococci, and is more effective than ampicillin against Enterobacteriaceae. The combination also holds promise as a treatment for soft tissue, bone and joint infections in children.
耐氨苄西林的b型流感嗜血杆菌菌株的出现和传播，导致在儿童严重感染的初始治疗中，氨苄西林的使用急剧减少，或添加了氯霉素。在某些情况下，会改用第三代头孢菌素。氨苄西林与舒巴坦的组合恢复了氨苄西林以前的效用，并扩大了其活性谱，使其包括通常对氨苄西林耐药的金黄色葡萄球菌。舒巴坦/氨苄西林在治疗细菌性脑膜炎方面应会有效。它在抗李斯特菌和肠球菌方面比第三代头孢菌素更有效，在抗肠杆菌科方面比氨苄西林更有效。该组合作为儿童软组织、骨骼和关节感染的治疗方法也有前景。
